Pharmacokinetics and protein binding of gestodene under treatment with a low-dose combination oral contraceptive for three months.
L Dibbelt, R Knuppen, W Kuhnz, G Jütting - Arzneimittel-forschung, 1992 - europepmc.org
The serum concentrations of gestodene (CAS 60282-87-3) as well as the binding of this
progestin to serum proteins were studied in 40 women who took a low-dose oral …
progestin to serum proteins were studied in 40 women who took a low-dose oral …
Pharmacokinetics and serum protein binding of gestodene and 3-keto-desogestrel in women after single oral administration of two different contraceptive formulations.
W Kuhnz, B Schütt, J Power, DJ Back - Arzneimittel-forschung, 1992 - europepmc.org
Two low-dose oral contraceptives, both containing the same dose of ethinyl estradiol (EE2,
CAS 57-63-6) but different progestins--gestodene (CAS 60282-87-3) and desogestrel (CAS …
CAS 57-63-6) but different progestins--gestodene (CAS 60282-87-3) and desogestrel (CAS …
Pharmacokinetics of gestodene and ethinylestradiol in 14 women during three months of treatment with a new tri-step combination oral contraceptive: serum protein …
W Kuhnz, A Baumann, T Staks, L Dibbelt, R Knuppen… - Contraception, 1993 - Elsevier
The pharmacokinetics of gestodene (GEST) and ethinylestradiol (EE 2) were determined in
14 healthy women (age 18 to 32 years) during a treatment period of three months with a new …
14 healthy women (age 18 to 32 years) during a treatment period of three months with a new …
Pharmacokinetics of gestodene and ethinyl estradiol after oral administration of a monophasic contraceptive
U Täuber, W Kuhnz, M Hümpel - American journal of obstetrics and …, 1990 - Elsevier
The pharmacokinetic and protein-binding properties of gestodene and ethinyl estradiol have
been investigated after single and multiple dosing in several studies in 83 healthy, young …
been investigated after single and multiple dosing in several studies in 83 healthy, young …
Serum distribution of two contraceptive progestins: 3-ketodesogestrel and gestodene
GL Hammond, WP Bocchinfuso, M Orava, CL Smith… - Contraception, 1994 - Elsevier
A cross-over study of two oral contraceptive formulations, containing 30 μg ethinylestradiol
in combination with 150 μg desogestrel (Marvelon®) or 75 μg gestodene (Femovan®), has …
in combination with 150 μg desogestrel (Marvelon®) or 75 μg gestodene (Femovan®), has …
Alterations in the serum levels of gestodene and SHBG during 12 cycles of treatment with 30 μg ethinylestradiol and 75 μg gestodene
H Kuhl, C Jung-Hoffmann, F Heidt - Contraception, 1988 - Elsevier
The serum concentrations of gestodene have been measured radioimmunologically in 11
female volunteers on Day 1, 10, and 21 of the 1st, 3rd, 6th, and 12th cycle of treatment with …
female volunteers on Day 1, 10, and 21 of the 1st, 3rd, 6th, and 12th cycle of treatment with …
Gestodene: a novel synthetic progestin—characterization of binding to receptor and serum proteins
K Pollow, M Juchem, HJ Grill, W Elger, S Beier… - Contraception, 1989 - Elsevier
Abstract Gestodene, 17α-ethinyl-13-ethyl-17β-hydroxy-4, 15-gonadien-3-one, is a new
orally active progestational agent, which is available for clinical use in oral contraceptives …
orally active progestational agent, which is available for clinical use in oral contraceptives …
Pharmacokinetics of gestodene in 12 women who received a single oral dose of 0.075 mg gestodene and, after a wash-out phase, the same dose during one …
W Kuhnz, C Gansau, A Fuhrmeister - Contraception, 1992 - Elsevier
The pharmacokinetics of gestodene (GEST) was determined in 12 healthy women (age 22
to 34 years), following single dose administration of 0.075 mg GEST. The same preparation …
to 34 years), following single dose administration of 0.075 mg GEST. The same preparation …
Single dose phakmacokinetics of gestodene in women after intravenous and oral administration
U Täuber, JW Tack, H Matthes - Contraception, 1989 - Elsevier
Six healthy female volunteers (age 25–39 years) received 75 μg gestodene intravenously
followed by 3 oral administrations of 25, 75 and 125 μg gestodene together with 30 μg …
followed by 3 oral administrations of 25, 75 and 125 μg gestodene together with 30 μg …
Pharmacological and endocrine profiles of gestodene.
J Spona, J Huber - International Journal of Fertility, 1987 - europepmc.org
Efforts to minimize oral contraceptive side effects have focused on the use of new dosage
schemes and the synthesis of new steroids that can be used in safer, low-dose formulations …
schemes and the synthesis of new steroids that can be used in safer, low-dose formulations …